Medserv - Strong year in progress
With a strong revenue and profit contribution from the Suriname contract, H119 group performance was excellent. The timing of the project should mean there is a stronger H219 performance, although FY20 group revenue prospects are impaired by the anticipated end to activity early in the year. Existing prospects in Cyprus, Egypt and elsewhere support our FY20 estimates and should be augmented by several major new projects that could be captured in the coming months for both the ILSS and OCTG divisions. Medserv’s international expansion with an increasing number of IOCs is spreading the risk, and for the time being we expect the company to deliver progressively improving profitability and cash flows.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.